Effects of growth hormone and prolactin on hematopoiesis.
The use of the neuroendocrine hormones growth hormone (GH) and prolactin (PRL) in preclinical models, demonstrating promotion of hematopoietic recovery and immune function, offers promise for several clinical situations. These hormones do not appear to produce the same extent of immune/hematopoietic effects when compared to conventional hematopoietic and immune stimulating cytokines (i.e. G-CSF or interleukin-2). However, their pleiotropic effects and limited toxicity after systemic administration makes them attractive to test in myeloablative situations. More work needs to be performed to understand the mechanism(s) of GH and PRL action, particularly with regard to hematopoietic progenitor cell expansion and differentiation both in normal and pathologic situations.
Welniak
L A
LA
Laboratory of Leukocyte Biology, National Cancer Institute-Frederick Cancer Research and Development Center, MD 21702-1201, USA.
Tian
Z G
ZG
Sun
R
R
Keller
J R
JR
Richards
S
S
Ruscetti
F W
FW
Murphy
W J
WJ
D000818:Animals; D013006:Growth Hormone / Q000494:pharmacology* / Q000502:physiology*; D006410:Hematopoiesis / Q000187:drug effects* / Q000502:physiology*; D006801:Humans; D011388:Prolactin / Q000494:pharmacology* / Q000502:physiology*; D015398:Signal Transduction
D011388:Prolactin; D013006:Growth Hormone